RedHill Biopharma RDHL Stock
RedHill Biopharma Price Chart
RedHill Biopharma RDHL Financial and Trading Overview
| RedHill Biopharma stock price | 0.42 USD |
| Previous Close | 0.46 USD |
| Open | 0.46 USD |
| Bid | 0.36 USD x 3000 |
| Ask | 0.52 USD x 100 |
| Day's Range | 0.43 - 0.46 USD |
| 52 Week Range | 0.43 - 1.82 USD |
| Volume | 97.55K USD |
| Avg. Volume | 2.06M USD |
| Market Cap | 3.85M USD |
| Beta (5Y Monthly) | 4.899 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RDHL Valuation Measures
| Enterprise Value | -1766991 USD |
| Trailing P/E | N/A |
| Forward P/E | 14.433333 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 0.51670647 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.224 |
Trading Information
RedHill Biopharma Stock Price History
| Beta (5Y Monthly) | 4.899 |
| 52-Week Change | -73.69% |
| S&P500 52-Week Change | 15.11% |
| 52 Week High | 1.82 USD |
| 52 Week Low | 0.43 USD |
| 50-Day Moving Average | 0.58 USD |
| 200-Day Moving Average | 0.84 USD |
RDHL Share Statistics
| Avg. Volume (3 month) | 2.06M USD |
| Avg. Daily Volume (10-Days) | 1.71M USD |
| Shares Outstanding | 8.89M |
| Float | 4.2M |
| Short Ratio | 0.04 |
| % Held by Insiders | 4680.63% |
| % Held by Institutions | 3.47% |
| Shares Short | 211.2K |
| Short % of Float | 2.39% |
| Short % of Shares Outstanding | 2.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.37% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0.09 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 0 USD |
| EBITDA | -7903000 USD |
| Net Income Avi to Common (ttm) | -10866000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.16M USD |
| Total Cash Per Share (mrq) | 1.01 USD |
| Total Debt (mrq) | 1.08M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.335 |
| Book Value Per Share (mrq) | 0.838 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7764000 USD |
| Levered Free Cash Flow (ttm) | 5.19M USD |
Profile of RedHill Biopharma
| Country | United States |
| State | N/A |
| City | Tel Aviv-Yafo |
| Address | 21 Ha’arba’a Street |
| ZIP | 6473921 |
| Phone | 972 3 541 3131 |
| Website | https://www.redhillbio.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Q&A For RedHill Biopharma Stock
What is a current RDHL stock price?
RedHill Biopharma RDHL stock price today per share is 0.42 USD.
How to purchase RedHill Biopharma stock?
You can buy RDHL shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RedHill Biopharma?
The stock symbol or ticker of RedHill Biopharma is RDHL.
Which industry does the RedHill Biopharma company belong to?
The RedHill Biopharma industry is Drug Manufacturers - Specialty & Generic.
How many shares does RedHill Biopharma have in circulation?
The max supply of RedHill Biopharma shares is 8.89M.
What is RedHill Biopharma Price to Earnings Ratio (PE Ratio)?
RedHill Biopharma PE Ratio is now.
What was RedHill Biopharma earnings per share over the trailing 12 months (TTM)?
RedHill Biopharma EPS is 0 USD over the trailing 12 months.
Which sector does the RedHill Biopharma company belong to?
The RedHill Biopharma sector is Healthcare.
RedHill Biopharma RDHL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26008.86 USD — |
-2.6
|
7.66B USD — | 25918.09 USD — | 26359.41 USD — | — - | 7.66B USD — |
|
US Tech Health Care
IXHC
US
|
1340.89 USD — |
-0.01
|
— — | 1326.18 USD — | 1351.47 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32130.04 USD — |
-2.6
|
— — | 32017.91 USD — | 32563.09 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2001.45 USD — |
-1.71
|
— — | 1990.64 USD — | 2027.31 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7072.22 USD — |
-0.75
|
— — | 6984.81 USD — | 7181.98 USD — | — - | — — |
- {{ link.label }} {{link}}
